HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acneiform Eruption Due to Chemical
Conditions
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Trial Timeline
Jul 19, 2023 → Dec 30, 2026
NCT ID
NCT05639933About HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 Placebo
HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 Placebo is a phase 2 stage product being developed by Hoth Therapeutics for Acneiform Eruption Due to Chemical. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05639933. Target conditions include Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05639933 | Phase 2 | Recruiting |
Competing Products
2 competing products in Acneiform Eruption Due to Chemical
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topical Dapsone 5% Gel + oral antibiotics | Bristol Myers Squibb | Phase 3 | 76 |
| Imsidolimab + Placebo | Vanda Pharmaceuticals | Phase 2 | 44 |